Synta Pharmaceuticals

Synta Pharmaceuticals doesn't fill stockings, but it might eventually fill the medical need of treating cancer. The drug development company has a handful of candidates in clinical and pre-clinical development stages. Its ganetespib and elesclomol compounds are in clinical trials as possible treatments for several types of cancer, including non-small cell lung cancer (NSCLC), acute myeloid leukemia, melanoma, and rectal, pancreatic, ovarian, prostate, and breast cancers. Synta's preclinical research efforts include potential therapies for autoimmune diseases, transplant acceptance, respiratory conditions, and cancerous tumors.